2011
Boosting enrolment in clinical trials: validation of a regional network model
Kernan W, Viscoli C, Brass L, Amatangelo M, Birch A, Clark W, Conwit R, Furie K, Gorman M, Pesapane B, Kleindorfer D, Lovejoy A, Osborne J, Silliman S, Zweifler R, Horwitz R. Boosting enrolment in clinical trials: validation of a regional network model. Clinical Trials 2011, 8: 645-653. PMID: 21824978, PMCID: PMC3852692, DOI: 10.1177/1740774511414925.Peer-Reviewed Original ResearchConceptsClinical trialsTransient ischemic attackNames of patientsEligible patientsIschemic attackStroke preventionDrug adherenceStroke therapyActive surveillanceAverage monthly rateHome visitsPatientsHospitalTrial researchParticipant costsOutreach NetworkMultiple hospitalsTrialsStudy intervalNational InstituteEnrollmentMonthly rateStrokeParticipantsReproducible method
2009
Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONs)
Kernan WN, Viscoli CM, DeMarco D, Mendes B, Shrauger K, Schindler JL, McVeety JC, Sicklick A, Moalli D, Greco P, Bravata DM, Eisen S, Resor L, Sena K, Story D, Brass LM, Furie KL, Gutmann L, Hinnau E, Gorman M, Lovejoy AM, Inzucchi SE, Young LH, Horwitz RI. Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONs). Neurology 2009, 72: 1345-1351. PMID: 19365056, PMCID: PMC2677492, DOI: 10.1212/wnl.0b013e3181a0fda3.Peer-Reviewed Original ResearchConceptsOutreach NetworkCentral coordinating centerInsulin Resistance InterventionSecondary stroke preventionNames of patientsResults of surveillanceStroke preventionMore patientsStroke siteConnecticut hospitalsTrial participantsHome visitsPatientsResistance InterventionPersonal physicianElectronic admissionRandomization ratesCoordinating CenterMore rapid completionMonthsHigher enrollment ratesHospitalRecruitment strategiesTrialsParticipants
2003
Use of Ephedra-containing products and risk for hemorrhagic stroke
Kernan W, Brass L, Viscoli C, Broderick J, Brott T, Feldmann E, Wilterdink J, Morgenstern L. Use of Ephedra-containing products and risk for hemorrhagic stroke. Neurology 2003, 61: 725. PMID: 12963785, DOI: 10.1212/wnl.61.5.724.Peer-Reviewed Original Research
1989
Ceftriaxone Compared with Cefotaxime for Serious Bacterial Infections
Smith C, Petty B, Hendrix C, Kernan W, Garver P, Fox K, Beamer A, Carbone K, Threlkeld M, Lietman P. Ceftriaxone Compared with Cefotaxime for Serious Bacterial Infections. The Journal Of Infectious Diseases 1989, 160: 442-447. PMID: 2668428, DOI: 10.1093/infdis/160.3.442.Peer-Reviewed Original ResearchMeSH KeywordsAdultBacteriaBacterial InfectionsCefotaximeCeftriaxoneClinical Trials as TopicDrug Administration ScheduleFemaleHumansMaleMiddle AgedConceptsSerious bacterial infectionsBacterial infectionsDouble-blind clinical trialSuspected serious bacterial infectionResponse rateCefotaxime 2 gCeftriaxone 2 gDose of ceftriaxoneTreatment groupsDose of cefotaximeFrequency of diarrheaClinical responseAnaerobic infectionsProthrombin timeCeftriaxoneClinical trialsCefotaximeInfecting organismInfectionAdverse effectsDoseTreatmentDaysThrombophlebitisProthrombin